| Date Filed | Type | Description |
| 08/21/2023 |
4
| Weinand Dieter (Director) has filed a Form 4 on Coya Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $3.43, valued at
$34.3k
|
|
| 08/21/2023 |
3
| Weinand Dieter (Director) has filed a Form 3 on Coya Therapeutics, Inc. |
| 08/21/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/19/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/14/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/12/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/23/2023 |
8-K
| Other Events Interactive Data |
| 05/19/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/16/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/12/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 05/11/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/08/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/22/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 03/21/2023 |
8-K
| Investor presentation |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/01/2023 |
4
| Berman Howard (CEO) has filed a Form 4 on Coya Therapeutics, Inc.|
Txns:
| Granted 165,000 options to buy
@ $3.85, valued at
$635.3k
|
|
| 03/01/2023 |
4
| Hepner Adrian (Chief Medical Officer) has filed a Form 4 on Coya Therapeutics, Inc.|
Txns:
| Granted 115,000 options to buy
@ $3.85, valued at
$442.8k
|
|
| 03/01/2023 |
4
| SNYDER DAVID S (CFO) has filed a Form 4 on Coya Therapeutics, Inc.|
Txns:
| Granted 115,000 options to buy
@ $3.85, valued at
$442.8k
|
|
| 02/14/2023 |
SC 13G
| Berman Howard reports a 14.2% stake in COYA THERAPEUTICS, INC. |
| 01/25/2023 |
8-K
| Other Events Interactive Data |
|